Not Yet RecruitingPhase 2

Clinical Study of HRS-2129 for Acute Gouty Arthritis

China90 participantsStarted 2026-07

Plain-language summary

The study is being conducted to evaluate the safety, and efficacy of HRS-2129 for acute gouty arthritis. To explore the reasonable dosage of HRS-2129 for acute gouty arthritis.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Able and willing to provide a written informed consent
. Subjects requiring Acute gouty arthritis
. Target joint VAS pain score ≥ 50 mm (screening)

Exclusion criteria

. Subjects with a history of severe allergies
. Subjects with nervous system disease
. Subjects with a history of mental illness
. Subjects with abnormal liver and renal function
. Subjects with poorly controlled hypertensive
. QTc：\>450ms（male），\>470ms（female）
. History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)
. The investigators determined that other conditions were inappropriate for participation in this clinical trial

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change from baseline inVisual Analogous Scale pain score at 24 hours post first dose

Timeframe: from ICF signing date to 24 hours after first dose

Trial details

NCT IDNCT07706777

SponsorShandong Suncadia Medicine Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-10

Contact for this trial

Lei Tang

+0518-82342973 lei.tang.lt31@hengrui.com

View on ClinicalTrials.gov More Acute Gouty Arthritis trials